Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
The Department of Microbiology
日本語
|
English
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
The Department of Microbiology

Research

Research on coronaviruses

At the time of the COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2: SARS-CoV-2) outbreak and pandemic, we were responsible for the respiratory virus division (Department of Virology 3) at the National Institute of Infectious Diseases (NIID). We were deeply involved in the laboratory diagnosis of Japan's first case, the nationwide deployment of diagnostic methods, the establishment of virus isolation techniques, the distribution of VeroE6/TMPRSS2 cells to hundreds of domestic and international sites, and the development of therapeutic agents. After transferring to the University of Tokyo in September 2022, we have continued our research on coronaviruses.


Main Related Publications

  1. Kakizaki M, Hashimoto R, Nagata N, Yamamoto T, Okura T, Katoh H, Kitai Y, Akahori Y, Shirato S, Ryo A, Takayama K, Takeda M. The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids. J Virol. 2024 in press.
  2. Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M. Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. Nat Commun 13: 6100, 2022.Link
  3. Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S, Tanaka T, Kume Y, Chishiki M, Ono T, Moriishi K, Sonoyama M, Hosoya M, Hashimoto K, Maenaka K, Takeda M: Hydrophobic alpha-helical short peptides in overlapping reading frames of the coronavirus genome. Pathogens 11:877, 2022.Link
  4. Saso W, Yamasaki M, Nakakita S, Fukushi S, Tsuchimoto K, Watanabe N, Sriwilaijaroen N, Kanie O, Muramatsu M, Takahashi Y, Matano T, Takeda M, Suzuki Y, Watashi K: Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. PLOS Pathog 18:e1010590, 2022.Link
  5. Takashita E, inoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y: Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med 386:1475-1477, 2022.Link
  6. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y: Efficacy of antibodies and antivirals against COVID-19 omicron variant. N Engl J Med 386:995-998, 2022.Link
  7. Takeda M: Proteolytic activation of SARS-CoV-2 spike protein. Microbiol Immunol 66:15-23, 2022.Link
  8. Shirato K, Tomita Y, Katoh H, Yamada S, Fukushi S, Matsuyama S, Takeda M: Performance evaluation of real–time RT–PCR assays for detection of severe acute respiratory syndrome coronavirus–2 developed by the National Institute of Infectious Diseases, Japan. Jpn J Infect Dis 74:465-472,2021.
  9. Tomita Y, Takeda M, Matsuyama S. (2021) The anti–influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells. Antimicrob Agents Chemother 65:e00020–21, 2021.Link
  10. Tomita Y, Matsuyama S, Fukuhara H, Maenaka K, Kataoka H, Hashiguchi T, Takeda M: The physiological TMPRSS2 inhibitor HAI–2 alleviates SARS-CoV-2 infection. J Virol 95:e00434–21, 2021.Link
  11. Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T: Potential anti–COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24:102367, 2021.
  12. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, Katho H, Sakata M, Nakatsu Y, Mori Y, Kageyama T, Matsuyama S, Takeda M: Development of genetic diagnositic methods for novel coronavirus 2019 (nCoV–2019) in Japan. Jpn J Infect Dis 73:304–307, 2020.
  13. Kato F, Matsuyama S, Kawase M, Hishiki T, Katoh H, Takeda M: Antiviral activities of mycophenolic acid and IMD–0354 against SARS-CoV-2. Microbiol Immunol 64:635–639, 2020.
  14. Imai M, Iwatsuki–Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai–Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y: Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 117:16587–16595, 2020.
  15. Matsuyama S*, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M: Enhanced isolation of SARS-CoV-2 by TMPRSS2–expressing cells. Proc Natl Acad Sci U S A 117:7001–7003, 2020.